Want to join the conversation?
On the guidance front, $XRX provided a 4Q15 GAAP earnings forecast of $0.23-0.25 per share. For FY15, GAAP earnings is forecasted at the low end of $0.46-0.52 per share & adjusted EPS at the low end of $0.95-1.01 per share. Cash flow from operations is expected between $1.6-1.7Bil for FY15 and free cash flow from operations between $1.3-1.4Bil.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.